GLPG.AS
Price:
$25.32
Market Cap:
$1.67B
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fib...[Read more]
Industry
Biotechnology
IPO Date
2005-05-06
Stock Exchange
EURONEXT
Ticker
GLPG.AS
According to Galapagos NV’s latest financial reports and current stock price. The company's current ROE is 7.20%. This represents a change of 294.53% compared to the average of 1.82% of the last 4 quarters.
The mean historical ROE of Galapagos NV over the last ten years is -3.53%. The current 7.20% ROE has changed -304.01% with respect to the historical average. Over the past ten years (40 quarters), GLPG.AS's ROE was at its highest in in the September 2019 quarter at 14.25%. The ROE was at its lowest in in the December 2015 quarter at -15.62%.
Average
-3.53%
Median
-3.58%
Minimum
-32.44%
Maximum
16.11%
Discovering the peaks and valleys of Galapagos NV ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 81.88%
Maximum Annual ROE = 16.11%
Minimum Annual Increase = -433.31%
Minimum Annual ROE = -32.44%
Year | ROE | Change |
---|---|---|
2023 | 7.57% | -187.75% |
2022 | -8.63% | 81.88% |
2021 | -4.74% | -59.26% |
2020 | -11.65% | -323.51% |
2019 | 5.21% | -316.25% |
2018 | -2.41% | -78.92% |
2017 | -11.43% | -260.60% |
2016 | 7.12% | -121.94% |
2015 | -32.44% | -301.36% |
2014 | 16.11% | -433.31% |
The current ROE of Galapagos NV (GLPG.AS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.93%
5-year avg
-2.45%
10-year avg
-3.53%
Galapagos NV’s ROE is greater than argenx SE (-2.75%), greater than Pharming Group N.V. (-8.08%), less than Barco NV (7.32%), less than Biocartis Group NV (203.74%), less than Koninklijke Ahold Delhaize N.V. (12.34%),
Company | ROE | Market cap |
---|---|---|
-2.75% | $35.06B | |
-8.08% | $586.78M | |
7.32% | $954.05M | |
203.74% | $27.24M | |
12.34% | $29.18B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Galapagos NV using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Galapagos NV or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Galapagos NV's ROE?
How is the ROE calculated for Galapagos NV (GLPG.AS)?
What is the highest ROE for Galapagos NV (GLPG.AS)?
What is the 3-year average ROE for Galapagos NV (GLPG.AS)?
What is the 5-year average ROE for Galapagos NV (GLPG.AS)?
How does the current ROE for Galapagos NV (GLPG.AS) compare to its historical average?